OraSure Investor Relations Material

OraSure Technologies, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices for testing for the presence of Hepatitis B surface antigen, human immunodeficiency virus type 1/2, antibiotic-resistant Neisseria gonorrhoeae resistance to antibiotics, human papillomavirus genotypes 16 and 18 in women aged 23 to 65 years are at increased risk of cervical cancer, discrimination based on drug abuse or HIV status; sexually transmitted infections; or male infertility. The company offers single use kits that are designed to evaluate oral fluid specimens collected using cheek swab samples; oral fluid collection device allowing collection of saliva specimens without venipuncture; OraQuick HIV-1/2 SureView test for qualitative detection of antigens and antibodies against HIV-1 and HIV-2